Could a gut bug help heal fatty liver? new trial begins

NCT ID NCT07488975

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing whether a pasteurized gut bacterium called Akkermansia muciniphila can help people with metabolic dysfunction-associated steatotic liver disease (MASLD), a common fatty liver condition. About 40 adults will take either a low, medium, or high dose of the bacterium or a placebo daily for 120 days. Researchers will measure changes in liver fat, stiffness, and fibrosis using scans and blood tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pasteurized Akkermansia muciniphila (a beneficial gut bacterium)
What this could lead to
If it works, this could point toward a new treatment for fatty liver disease that targets the gut-liver connection.
What could go wrong
This is a very early phase 1 trial with only 40 participants, so it is not yet proven to work in people. The benefits seen in animal studies may not translate to humans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Taiwan University Hospital

    RECRUITING

    Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.